Tango Therapeutics
Tango Therapeutics Inc is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. The firm focuses on the discovery and development of novel targeted cancer therapies using proprietary functional genomic discovery platforms. Its core research portfolio targets synthetic lethality to identify and attack cancer vulnerabilities across various tumor types. Revenue is primarily generated through research collaborations, corporate partnerships, and pharmaceutical licensing agreements. The company serves oncology researchers, healthcare institutions, and clinical development networks globally. Tango Therapeutics Inc is a publicly traded entity listed on the Nasdaq Stock Market.
10 of the funds FundTelligence covers report a position in Tango Therapeutics.
- Legal name
- Tango Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 10
- Exposure themes
- Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics
Funds holding Tango Therapeutics
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.16 % (full portfolio disclosed, September 2026)
- DNB Bioteknologi — DNB · 0.97 % (full portfolio disclosed, September 2026)
- Schroder ISF Healthcare Innovation — Schroders · 0.84 % (full portfolio disclosed, June 2026)
- JPM US Small Cap Growth Fund — JPM · 0.64 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.23 % (full portfolio disclosed, October 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.19 % (full portfolio disclosed, October 2026)
- Swedbank Robur Healthcare — Swedbank · 0.05 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 10 funds holding it.